MAX BioPharma reports on the inhibition of profibrotic signaling in cellular models of lung and kidney fibrosis by its oxysterol drug candidate, Oxy210, an orally available small molecule.

Please follow the link for a copy of the manuscript. https://www.mdpi.com/1424-8247/16/1/114